Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 12, 2024Value in HealthOpen Access

Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAmelia SmithKFKaren FinniganSCSarah Clarke

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Smith et al. (2024) studied this question.

synapsesocial.com/papers/68e6f602b6db6435876707e6https://doi.org/10.1016/j.jval.2024.04.002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study2026
  2. 2Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study2026
  3. 3Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis – a register-based cohort study2026 · 1 citations
  4. 4Mechanisms of therapeutic action of monoclonal antibodies to the calcitonin gene-related peptide (CGRP) ligand-receptor system in migraine2025
  5. 5Analysis of Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody and Antagonist Usage and Medication Switch Profile from a Tertiary Care Facility (P5-12.009)2024